A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia

Dean, B., Bakker, G., Ueda, H. R., Tobin, A. B. , Brown, A. and Kanaan, R. A. A. (2023) A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia. Frontiers in Cellular Neuroscience, 17, 1124333. (doi: 10.3389/fncel.2023.1124333) (PMID:36909280) (PMCID:PMC9992992)

[img] Text
293945.pdf - Published Version
Available under License Creative Commons Attribution.

1MB

Abstract

Pre-clinical models, postmortem and neuroimaging studies all support a role for muscarinic receptors in the molecular pathology of schizophrenia. From these data it was proposed that activation of the muscarinic M1 and/or M4 receptor would reduce the severity of the symptoms of schizophrenia. This hypothesis is now supported by results from two clinical trials which indicate that activating central muscarinic M1 and M4 receptors can reduce the severity of positive, negative and cognitive symptoms of the disorder. This review will provide an update on a growing body of evidence that argues the muscarinic M1 and M4 receptors have critical roles in CNS functions that are dysregulated by the pathophysiology of schizophrenia. This realization has been made possible, in part, by the growing ability to visualize and quantify muscarinic M1 and M4 receptors in the human CNS using molecular neuroimaging. We will discuss how these advances have provided evidence to support the notion that there is a sub-group of patients within the syndrome of schizophrenia that have a unique molecular pathology driven by a marked loss of muscarinic M1 receptors. This review is timely, as drugs targeting muscarinic receptors approach clinical use for the treatment of schizophrenia and here we outline the background biology that supported development of such drugs to treat the disorder.

Item Type:Articles
Keywords:Muscarinic M1 receptor, muscarinic M4 receptor, schizophrenia, sub-group, neuroimaging, postmortem CNS, xanomeline, KarXT.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Tobin, Andrew
Authors: Dean, B., Bakker, G., Ueda, H. R., Tobin, A. B., Brown, A., and Kanaan, R. A. A.
College/School:College of Medical Veterinary and Life Sciences > School of Molecular Biosciences
Research Centre:Mazumdar-Shaw Advanced Research Centre (ARC) > Technologies Touching Life
Journal Name:Frontiers in Cellular Neuroscience
Publisher:Frontiers Media
ISSN:1662-5102
ISSN (Online):1662-5102
Copyright Holders:Copyright © 2023 Dean, Bakker, Ueda, Tobin, Brown and Kanaan
First Published:First published in Frontiers in Cellular Neuroscience 17: 1124333
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record